Paolo Morelli’s Post

Medaffcon participated in the Radical Health Festival Helsinki event and Mariann Lassenius participated in the panel discussion. There was a good opportunity to reflect on the changes that have occurred over the past 10 years for research in Finland, and what the situation in #Sweden, Japan and Korea is at the moment, together with Michel Silvestri, Tomohiro Kuroda, and Lee Sangheon. "Finland’s robust framework for secondary data use positions it as a role model for the EHDS. Implementing changes stepwise is encouraged to enable a smooth transisitoning also during the establishment and implementation of the EHDS." , says Mariann Lassenius, RWE Lead at #Medaffcon. 🙏 Thank you for this opportunity Findata – Sosiaali- ja terveysalan tietolupaviranomainen | Social and Health Data Permit Authority and Radical Health Festival Helsinki ➡ If you want to hear more: info@medaffcon.fi ➡ Read more Medaffcon: https://lnkd.in/d69-SFXi #EHDS #pharma #research #RWE

It is a dream come true; I know it sounds like a shallow soundbite, but it is anything but… 6 years ago I had such a dream. The dream of patients being in control of their data, being able to measure how they are doing in a way that is understood by healthcare providers and being able to be to part of any decision that affects their lives. Not out of pity or compassion; but because they have the data and the evidence to prove their point. 6 years ago the #EHDS was not even at the horizon; however there is a tremendous opportunity for synergies now. The Pan-European Observatory can serve as a forum to achieve consensus on what can be measured digitally in routine care in order to improve care and fuel the EHDS with standardized outcome data. At the same time, the data access framework developed through the H2O project offers a blueprint on how to manage data by relying on the Patient Agreement. H2O through the leadership of the Pan-European Health Outcomes Observatory can pave the way on how to build the EHDS on the foundation of 'Data Trusts' and multi-stakeholder consensus on what to measure and how.

Did you know that real-world-evidence is a key component to understand how new innovations and technologies can be embedded to allow benefit for patient and the healthcare system? 📊Driving this type of research with access to high quality health datasources is crucial 🇫🇷That was one of many topics adressed during a two-day meeting at Novartis France in Paris 🙏Thanks Marion Pinet, Guillaume Wendt, PhD and Evgeniya Novoderezhkina, PhD for good collaboration in the planning and during the gathering 🌍A big thank you to the global team for joining and providing perspective- Adrian Cassidy, Elena Panitti, Luis Prieto 🤝Strong collaboration across countries in Europe is key to drive this area of interest further forward - combining key needs with world leading data-infrastructures we have in our countries🇬🇧🇩🇪🇫🇷🇳🇴🇸🇪🇫🇮🇩🇰 The Nordic team looks forward to future touchbases - Maija Wolf, Teresa Hallerbäck ,Björn Paulsson, Øyvind Fensgard, Jayson Swanson Habib Karam, Tobias Bäckström,Johan Kahlström, Jacob Brun ,Gerrit Zijlstra, Patrick Meshaka, Andre Schmidt Novartis Norge, Tony Terzis, Veronika Barrabes

📢Following the launch of the pan-European Health Outcomes Observatory, we are thrilled to introduce the newly appointed members of the Board. Congratulations to: 🔹 Dr Jørgen Schøler Kristensen (Chairman of the Danish Medicines Council), who will serve as Chair 🔹 Dr Linetta Koppert (Dutch H2O), who will serve as Vice-Chair 🔹Andreas Christodoulou (European Patients' Forum Board Member), who will join the Board as Treasurer; and 🔹Board Members Dr Matthias Rose (German H2O), Dr Pilar Rodriguez Ledo (Spanish H2O), and Héctor Röthlisberger. This marks a significant milestone for the H2O initiative, now including the pan-European Observatory and national observatories in Austria, Germany, the Netherlands, and Spain. We are eager to expand further, promoting patient empowerment and advancing health research across #Europe and beyond. Read our press release on the launch of the pan-European Health Outcomes Observatory 👉 https://lnkd.in/eMnc8WTF Innovative Health Initiative (IHI), EFPIA - European Federation of Pharmaceutical Industries and Associations, European Patients' Forum, Trial Nation, JDRF International, Teamit #InnovativeHealthInitiative #HealthcareInnovation #DataAnalytics #HealthOutcomes #HealthResearch #DataDrivenHealthcare #InnovateHealth #HealthcareRevolution

Starting Jan 2025, the new EU #Health #Technology Assessment Regulation (EU HTAR) will become a reality for #Oncology and #ATMPs (advanced therapy medicinal products). Aiming to foster transparency and quality in HTA procedures and promoting efficient use of public resources via a centralized approach, the EU HTAR holds great promise, but also poses challenges for health technology developers to tackle. In our recent conversations with a series of PharmaCos, it became clear that different approaches are being adopted to ensure readiness for the implementation of the new regulation - to turn challenges into opportunities. In collaboration with Thalita Marinho, Iryna (Stadnyk) Scheurlen, Burcu Yetkin, Khushbu Lalwani Goulden, Sebastian Schwärzler, João Aguiar Machado, Elina Osoianu, Lukas Rabl, and Armaan Bajaj, we explore the different approaches undertaken and offer a view on the key enablers to embrace the EU HTA implementation: https://lnkd.in/ecD8_YR4 Strategy& PwC #FutureOfHealth Christian Kaspar Dr. Jens Neumann Dr. Till Giese Dr. Christoph S Gross Jonas Grefe Kariem Schlieper Nalah Schneider Brian Selvarajah Oguz Ozden Roland Werner Dr. Robert Paffen Matthias Reyntjens Bodo Baumeister Mylène Jeandupeux Dominik Hotz Etienne Dreyer Nicolas Rowan Dr. Lingli He Ronald Chopoorian Johnathon Marshall Scott Lawson

Are you curious about how trends in real word evidence (RWE) are shaping decision-making in healthcare? Join us at #ISPORAnnual for an insightful research poster tour that includes insights for leveraging RWE in non-oncology submissions in the UK, France, and Germany. Taking place at PT43 on May 7 from 3:30-4:15, we'll provide a brief overview of our findings and engage in a lively discussion with delegates and the knowledgeable tour guide. Discover key insights from our analysis of health technology assessment (HTA) submissions to NICE, HAS, and the G-BA, including: - The prevalence of RWE in non-oncology submissions - Trends in the use and acceptability of RWE across different markets - Various ways RWE is utilized to support clinical effectiveness, tolerance, and cost-effectiveness. Authors: Ally Robert and Vasileios Pardalidis, Avalere Health. Meet us on the poster tour to gain valuable knowledge and contribute to the discussion. Meet us at Booth 413: https://lnkd.in/eAxvzZha #HEOR #MarketAccess #RWE #HTA #WeAreAvalereHealth

It was my pleasure to share insights and to discuss #innovation and how to do more with less #healthcare #genomics #clinicaltrials

Save the date and block your calendars! On March 5 & 6, 2025 we will be at the World Evidence, Pricing and Access Congress in Amsterdam. Listen to what Claire Everitt of Pfizer has to say about what the BEAMER project has accomplished and what the future has in store. And visit the combined BEAMER-Link2Trials booth to learn how you can benefit from this. #patientadherence #patientengagement #patientrecruitment #clinicaltrials #clinicaloperations #healthcareinnovations #healthcareprofessionals #patientoutcomes #patientcentricity #clinicalcare #patientexperience #healthjourney #patientjourney #patientparticipation #regulators #healthinsurancepolicy #beamerproject

Are you curious about how trends in real word evidence (RWE) are shaping decision-making in healthcare? Join us at #ISPORAnnual for an insightful research poster tour that includes insights for leveraging RWE in non-oncology submissions in the UK, France, and Germany. Taking place at PT43 on May 7 from 3:30-4:15, we'll provide a brief overview of our findings and engage in a lively discussion with delegates and the knowledgeable tour guide. Discover key insights from our analysis of health technology assessment (HTA) submissions to NICE, HAS, and the G-BA, including: - The prevalence of RWE in non-oncology submissions - Trends in the use and acceptability of RWE across different markets - Various ways RWE is utilized to support clinical effectiveness, tolerance, and cost-effectiveness. Authors: Ally Robert and Vasileios Pardalidis, Avalere Health. Meet us on the poster tour to gain valuable knowledge and contribute to the discussion. Schedule a meeting with us at Booth 413: https://lnkd.in/eAxvzZha #HEOR #MarketAccess #RWE #HTA #WeAreAvalereHealth

EPHA's 6th #AccesstoMedicines Forum was a huge success! Listen to some key insights from our distinguished panelists. 💠 Dr Sarah Garner, Senior Policy Advisor at WHO Regional Office for Europe, emphasizes the issues surrounding access to medicines, such as #affordability and budget challenges. She urges collaborative efforts among member states to achieve universal access. 💠 Anne Hendrickx of Solidaris Wallonie, discusses the importance of AIM - Association Internationale de la Mutualité/International Association of Mutuals's fair pricing calculator to determine concrete and fair prices for medicines. 💠 Dr. Dimitra Panteli, Program Manager at the European Observatory on Health Systems and Policies addresses barriers in antibiotic development and proposes a holistic solution model with push incentives, pull incentives, and aligning incentives. 💠 Helle Aagaard, Director of ReAct - Action on Antibiotic Resistance, illustrated how the EU #pharmaceutical package is not the solution to the problem of #AMR. Alternative incentive models should also be considered. 💠 Anna Prokůpková, Health Policy Advisor from the Greens/EFA Group at European Parliament, discussed the importance of improving #transparency within pharmaceuticals. 💠 Javier de la Cueva, a lawyer specialised in free intellectual property licenses, condemns the ownership of citizens' data by big companies and makes a strong case for #OpenScience. 💠 Dimitri Eynikel of Médecins Sans Frontières (MSF)'s Access Campaign discussed the challenges on global access to medicines, #vaccines & diagnostics especially in low- and middle-income countries. Watch all the interviews here ➡️https://lnkd.in/exDxdMNz